Cipla, a pharmaceutical company, announced on Wednesday that the Central Drugs Standard Control Organization has given it permission to market and distribute Afrezza inhalation powder in India.
The firm claims that Afrezza, a medicine developed and produced by MannKind Corporation (MannKind) USA, helps adult patients with diabetes mellitus achieve better glycemic control. Cipla will make this medication available to everyone and enable millions of people to more easily take charge of their health by introducing a revolutionary, patient-centered approach to diabetes treatment in India, the statement continued.
Cipla has partnered with Mankind Corporation to make Afrezza
Mankind Corporation created and produces Afrezza, which helps adult patients with diabetes mellitus improve their glycemic control.
Fast-acting inhaled insulin, known as Afrezza, is administered via an inhaler during meals. It takes 12 minutes to start working and lasts for two to three hours. It assists in rapidly regulating blood sugar levels, avoiding unexpected rises in blood sugar following meals.
In order to make Afrezza (Afrezza) available in the Indian market, Cipla has worked with Mankind Corporation. The firm hopes to make Afrezza freely accessible throughout the nation so that thousands of people can use it to better manage their health.
Cipla Q2 FY25 Results
Cipla, a prominent pharmaceutical company, announced on Tuesday that its consolidated net profit for the second quarter that ended in September 2024 increased by 17% to ₹1,303 crore, fueled by strong sales in all markets. In the July-September quarter of the previous fiscal year, the company generated a net profit of ₹1,115 crore. According to a regulatory filing, Cipla’s overall operating income increased to ₹7,051 crore in the second quarter from ₹6,490 crore in the same time last year.
Due to mix and other operational savings, we achieved the highest-ever EBITDA margin of 26.7% in Q2 FY25, with a 9% increase in revenue over the previous year,” stated Umang Vohra, MD and Global CEO of Cipla.
